publication date: Mar. 22, 2019

Texas cancer researchers vying to renew CPRIT beyond its 2023 sunset date

The institute is spending more than NCI in the state

­By Claire Dietz and Matthew Bin Han Ong

The Cancer Prevention and Research Institute of Texas—the second largest publicly-funded granting organization for cancer after NIH—may receive $3 billion more to stay open past its current sunset date in 2023.

The Texas state legislature is considering bills designed to repeal time limitations on CPRIT—Senate Bill 438, led by Texas Sen. Jane Nelson, and House Bill 39, led by Texas Rep. John Zerwas.

House Joint Resolution 12, also led by Zerwas, would authorize another $3 billion in general obligation bonds for cancer research and prevention to be submitted to voters at the general election on Nov. 5.

If these bills are passed, CPRIT will once again be put to the ballot, and Texas voters will be asked to approve another constitutional amendment, a requirement for reauthorizing the institute.

In their current versions, the House and Senate bills don’t specify the number of years for CPRIT’s reauthorization.

In fiscal year 2018, Texas institutions received $276 million from CPRIT and $250 million from NCI.

Over the years, funding from CPRIT allowed Texas institutions to attract top-tier researchers, including, famously, James Allison, who won the 2018 Nobel Prize in Physiology or Medicine for his work on immune checkpoint inhibition.

Allison was recruited to MD Anderson from Memorial Sloan Kettering Cancer Center in 2011. He is now chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, director of the Parker Institute for … Continue reading Texas cancer researchers vying to renew CPRIT beyond its 2023 sunset date

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.